Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess

References

• FranksS. Polycystic ovary syndrome in adolescents. Int J Obes (Lond) 2008;32:1035–1041.
   PubMedGoogle Scholar
• IbáñezL, de ZegherF. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004;89:1592–1597.
   PubMed Web of Science ®Google Scholar
• TarkunI, ArslanBC, CantürkZ, TüremenE, SahinT, DumanC. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004;89:5592–5596.
   PubMed Web of Science ®Google Scholar
• IbáñezL, de ZegherF. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update 2006;12:243–252.
   PubMed Web of Science ®Google Scholar
• GambineriA, PattonL, VaccinaA, CacciariM, Morselli-LabateAM, CavazzaC, PagottoU, PasqualiR. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 2006;91:3970–3980.
   PubMed Web of Science ®Google Scholar
• IbáñezL, DíazR, López-BermejoA, MarcosMV. Clinical spectrum of premature pubarche: links to metabolic syndrome and ovarian hyperandrogenism. Rev Endocr Metab Disord 2009;10:63–76.
   PubMed Web of Science ®Google Scholar
• IbáñezL, VallsC, PotauN, MarcosMV, de ZegherF. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low birthweight effect. Clin Endocrinol 2001;55:667–672.
   PubMedGoogle Scholar
• RosenfieldRL. Clinical review: identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:787–796.
   PubMed Web of Science ®Google Scholar
• IbáñezL, FerrerA, OngK, AminR, DungerD, de ZegherF. Insulin sensitization early post-menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr 2004;144:23–29.
   PubMedGoogle Scholar
• OngK, de ZegherF, López-BermejoA, DungerDB, IbáñezL. Flutamide-metformin for young post-menarcheal girls with preclinical androgen excess: evidence for differential response by androgen receptor genotype. Eur J Endocrinol 2007;157:661–668.
   PubMedGoogle Scholar
• FuruhashiM, HotamisligilGS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008;7:489–503.
   PubMed Web of Science ®Google Scholar
• CabréA, LázaroI, GironaJ, ManzanaresJM, MarimónF, PlanaN, HerasM, MasanaL. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 2007;195:e150–e158.
   PubMedGoogle Scholar
• LlaveriasG, NoéV, PeñuelasS, Vázquez-CarreraM, SánchezRM, LagunaJC, CiudadCJ, AlegretM. Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochem Biophys Res Commun 2004;318:265–274.
   PubMedGoogle Scholar
• XuA, WangY, XuJY, StejskalD, TamS, ZhangJ, WatNM, WongWK, LamKS. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006;52:405–413.
   PubMed Web of Science ®Google Scholar
• XuA, TsoAW, CheungBM, WangY, WatNM, FongCH, YeungDC, JanusED, ShamPC, LamKS. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007;115:1537–1543.
   PubMed Web of Science ®Google Scholar
• YeungDC, XuA, CheungCW, WatNM, YauMH, FongCH, ChauMT, LamKS. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:1796–1802.
   PubMed Web of Science ®Google Scholar
• RheeEJ, LeeWY, ParkCY, OhKW, KimBJ, SungKC, KimBS. The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol 2009;160:165–172.
   PubMedGoogle Scholar
• MiyoshiT, OnoueG, HirohataA, HirohataS, UsuiS, HinaK, KawamuraH, DoiM, KusanoKF, KusachiS, Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis 2010;211:164–169.
   PubMed Web of Science ®Google Scholar
• CabréA, LázaroI, GironaJ, ManzanaresJM, MarimónF, PlanaN, HerasM, MasanaL. Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J Lipid Res 2008;49:1746–1751.
   PubMedGoogle Scholar
• CollB, CabreA, Alonso-VillaverdeC, LazaroI, AragonésG, ParraS, GironaJ, MasanaL. The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis 2008;199:147–153.
   PubMedGoogle Scholar
• WesterbackaJ, KolakM, KiviluotoT, ArkkilaP, SirénJ, HamstenA, FisherRM, Yki-JärvinenH. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 2007;56:2759–2765.
   PubMed Web of Science ®Google Scholar
• FuruhashiM, FuchoR, GörgünCZ, TuncmanG, CaoH, HotamisligilGS. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 2008;118:2640–2650.
   PubMed Web of Science ®Google Scholar
• MöhligM, WeickertMO, GhadamgadaiE, MachlittA, PfüllerB, ArafatAM, PfeifferAF, SchöflC. Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women. Eur J Endocrinol 2007;157:195–200.
   PubMed Web of Science ®Google Scholar
• IbáñezL, López-BermejoA, DiazM, MarcosMV, de ZegherF. Metformin treatment for 4 yr to reduce total and visceral fat in low-birthweight girls with precocious pubarche. J Clin Endocrinol Metab 2008;93:1841–1845.
   PubMedGoogle Scholar
• Ferrández-LongásA, MayayoE, LabartaJI, BaguéL, PugaB, RuedaC, Ruiz-EcharriM, LabenaC. Estudio longitudinal de crecimiento y desarrollo. Centro Andrea Prader. Zaragoza 1980–2002. Patrones de crecimiento y desarrollo en España. Atlas de gráficas y tablas. In: Garcia-DihinxJ, RomoA, FerrándezA, editors. Madrid: ERGON2004. pp 61–115.
   Google Scholar
• SongJ, RenP, ZhangL, WangXL, ChenL, ShenYH. Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4. Biochem Biophys Res Commun 2010;393:89–94.
   PubMedGoogle Scholar